Nanotechnology Now - Press Release: Novel gene therapy shows potential for lung repair in asthma

Home > Press > Novel gene therapy shows potential for lung repair in asthma

Treatment for asthma.

CREDIT: ATS

Abstract:
Abstract 7875
Thymulin Gene Therapy Delivered by a New Biodegradable DNA Nanoparticle in Experimental Chronic Allergic Asthma
A.L. Da Silva1, G.P. Oliveira1, J.Z. Kitoko1, N.G. Blanco1, J.S. Suk2, J. Hanes2, P.C. Olsen1, M.M. Morales1, P.R.M. Rocco1 1Federal University of Rio de Janeiro - Rio De Janeiro/BR, 2Johns Hopkins University - Baltimore, MD/US Abstract Body

Rationale: Gene carrier penetration through an inflamed and remodeled airway, such as that found in asthma, is a prerequisite for successful gene therapy of such conditions. Our group recently reported that thymulin (serum thymic factor) gene transfection mediated by highly compacted DNA nanoparticles effectively prevents the inflammatory and remodeling process in asthmatic lungs, enhancing airway repair and thus improving lung mechanics in a mouse model of allergic asthma. However, a physical approach is necessary to improve the pharmacological properties of this molecule. In this line, we evaluated the effects of thymulin gene therapy delivered by a novel, nontoxic, biodegradable platform for DNA compaction in experimental asthma. We hypothesized that thymulin analog gene delivery by biodegradable DNA nanoparticles harboring a synthetic DNA sequence (5'-ATGCAAGCCAAATCTCAAGGTGGATCCAACTAGTAG-3') encoding a biologically active analog of thymulin (methionine-FTS) would reduce lung inflammation and remodeling in a murine model of allergic asthma.

Methods: Nanoparticles were formulated and characterized. Female BALB/c mice (weight 20-25 g) were then randomly assigned across four groups (n=8/group). In the OVA group, mice were immunized and challenged with ovalbumin. Control mice (CTRL) received saline under the same protocol. Twenty-four hours after the last challenge, animals were intratracheally treated with saline (NaCl 0.9%; CTRL and OVA-SAL groups), one dose of DNA nanoparticles (50 mcg thymulin DNA; OPBAE1d group), or three doses of DNA nanoparticles (150 mcg thymulin DNA; OPBAE3d group). After 20 days, animals were anesthetized and lung mechanics and histology analyzed.

Results: Immediately after the last ovalbumin challenge and at 20 days, OVA group animals exhibited eosinophil infiltration, increased collagen fiber in both airway and alveolar septa, and airway hyperresponsiveness, with no significant differences between time points. DNA nanoparticles exhibited a near-neutral charge and a hydrodynamic diameter of 45.6±2.6 nm. OPBAE1d mice exhibited reduced total leukocyte, TCD8+ lymphocyte, macrophage, and eosinophil counts, fraction area of alveolar collapse, and bronchoconstriction index compared to OVA-SAL, thus leading to a significant decrease in airway resistance. In OPBAE3d animals, fraction area of alveolar collapse and bronchoconstriction index were reduced, but total leukocyte counts were higher compared to OVA-SAL animals.

Conclusions: In this model of allergic asthma, a single dose of thymulin gene therapy delivered by a novel biodegradable platform was effective at reducing lung inflammation and improving lung histology and function.

Novel gene therapy shows potential for lung repair in asthma

San Francisco, CA | Posted on May 18th, 2016

A new study has demonstrated a way to deliver a nanoparticle-based gene therapy, in order to repair lungs damaged by chronic allergic asthma and to reduce inflammation that causes asthma attacks. The potential therapy, tested in mice, may hold promise for asthma patients whose disease is not controlled by the most commonly used treatments. The study was presented at the ATS 2016 International Conference.

"We found that a single dose of highly compacted DNA nanoparticle thymulin gene therapy effectively reduces the inflammatory and remodeling process in asthmatic lungs," said lead author Adriana Lopes da Silva, PhD, from the Federal University of Rio de Janeiro, Brazil. "This is especially important because some patients do not benefit from long-lasting beta2-agonists and inhaled corticosteroids, which are the most widely used asthma therapies."

In asthma, airways become inflamed, resulting in narrowing of these airways and debilitating symptoms that include coughing, wheezing, shortness of breath and chest tightness. Asthma and other respiratory diseases also cause changes in the large and small airways of the lungs, known as "remodeling." Remodeling is believed to be caused by long-term inflammation, and leads to worsening of patients' asthma.

"Alternative therapeutic approaches that can both reduce inflammatory and remodeling processes by overexpressing or inhibiting specific genes in the asthma inflammatory cascade, in different types of asthma and without leading to immunosuppression, are sorely needed," Dr. da Silva said.

Dr. da Silva's group recently found that the insertion of a thymulin analog gene into a plasmid (a type of DNA fragment) by using DNA nanoparticles enhances airway repair and improves lung function in a mouse model of allergic asthma. The current study looked at how to deliver this molecule in order to improve its therapeutic effects.

In the new study, Dr. da Silva and colleagues formulated and characterized the thymulin nanoparticles. Laboratory-bred female mice were then randomly assigned across four groups (n=8/group). In the OVA group, mice were immunized and challenged with ovalbumin, a type of protein found in egg whites that is a common allergen. Control mice (CTRL) received saline under the same protocol. Twenty-four hours after the last challenge, animals received injections of saline (CTRL and OVA-SAL groups), one dose of DNA nanoparticles, or three doses of DNA nanoparticles. After 20 days, the researchers examined the animals' lungs.

The researchers found that a single dose of thymulin gene therapy, which was delivered using a novel biodegradable platform, was effective at reducing lung inflammation and improving airway structure and function.

"We now need to better understand the mechanisms behind this therapeutic strategy," said Dr. da Silva. "We hope to then start Phase I trials in the near future."

###

Session: D21 Asthma Treatment: Glucocorticoids, Biologicals and Beyond
Wednesday, May 18, 2016, 9 a.m.
Location: Room 2010/2012 (West Building, Level 2), MOSCONE CENTER

####

For more information, please click here

Contacts:
Dacia Morris

212-315-8620

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark: